ランキング
お知らせ
ログイン
ランキング
お知らせ
ログイン
雑誌詳細
文献概要
増大特集 ギラン・バレー症候群のすべて—100年の軌跡
ギラン・バレー症候群の治療
著者： 野村恭一1
所属機関： 1埼玉医科大学総合医療センター神経内科
ページ範囲：P.1397 - P.1410
ギラン・バレー症候群（GBS）の治療は，1950年代までは主に対症療法のみであった。1950〜1960年代に副腎皮質ステロイド療法が導入されたが，その後のランダム化比較試験（RCT）の結果からステロイド剤単独治療の有効性は否定された。1970〜1980年代には血漿交換療法（PE）が導入され，大規模RCTによりその有効性が確認された。1990〜2000年代には免疫グロブリン静注療法（IVIg）が行われ，PEを対照とした多施設RCTを施行し，IVIgはPEに勝るとも劣らない治療法であることが確立した。さらに，2010年代には生物製剤を用いた新たな治療法が試みられている。
参考文献
1) Burns TM: Guillain-Barré syndrome. Semin Neurol 28: 152-167, 2008
2) Yuki N, Hurtung HP: Guillain-Barré syndrome. New Engl J Med 366: 2294-2304, 2012
3) Shy GM, McEachern D: Further studies of the effects of cortisone and ACTH on neurological disorders. Brain 74: 354-362, 1951
4) Jackson RH, Miller H, Schapira K: Polyradiculitis (Landry-Guillain-Barré syndrome). Treatment with cortisone and corticotrophin. Br Med J 1: 480-484, 1957
5) Heller GL, Dejong RN, Mich AA: Treatment of the Guillain-Barré syndrome. Use of corticotrophin and glucocorticoids. Arch of Neurol 8: 179-193, 1963
6) Wiederholt WC, Mulder DW, Lambert EH: The Landry-Guillain-Barré-Strohl syndrome or polyradiculoneuropathy-histotical review, report on 97 patients and present concepts. Mayo Clin Proc 39: 427-451, 1964
7) Frick E, Angstwurm H: Zur Kortikosteroid-Behandlung der idiopathischen Polyneuritis. Munch Med Wochenschr 110: 1265-1270, 1968
8) Newman MJ, Nelson N: Treatment of subacute polyneuritis with corticosteroids. Can J Neurol Sci 1: 180-184, 1974
9) Goodall JAD, Kosmidis JC, Geddes AM: Effect of corticosteroids on course of Guillain-Barré syndrome. Lancet 1: 524-526, 1974
10) Löffel NB, Rossi LN, Mumenthaler M, Lütschg J, Ludin HP: The Landry-Guillan-Barré syndrome Complications, prognosis and natural history in 123 cases. J Neurol Sci 33: 71-79, 1977
11) Samantray SK, Johnson SC, Mathai KV, Pulimood BM: Landry-Guillan-Barré-Strohl syndrome. A study of 302 cases. Med J Aust 2: 84-91, 1977
12) Hughes RAC, Newsom-Davis JM, Perkin GD, Pierce JM: Controlled trial of prednisolone in acute polyneuropathy. Lancet 2: 750-753, 1978
13) 高瀬貞夫, 沖田 直, 佐久間博明: Guillain-Barré症候群の治療. 神経治療1: 215-224, 1984
14) Dowling PC, Bosch VV, Cook SD: Possible beneficial effect of high-dose intravenous steroid therapy in acute demyelinating disease and transverse myelitis. Neurology 30: 33-36, 1980
15) Haaβ A, Trabert W, Greβnich N, Schimrigk K.: High-dose steroid therapy in Guillain-Barré syndrome. J Neuroimmunol 20: 305-308, 1988
16) Prestone DC, Logigian EL: Guillain-Barré syndrome during high-dose methylprednisone therapy. Muscle Nerve 14: 378-379, 1991
17) 沖田 直, 望月るり子, 関 久友, 飛田宗重, 高瀬貞夫: Guillain-Barré症候群に対するパルス療法の試み. 神経内科治療7: 347-352, 1990
18) Hughes RAC: Ineffectiveness of high-dose intravenous methylprednisolone in Guillain-Barré syndrome. Lancet 2: 1142, 1991
19) Guillain-Barré syndrome Steroid Trial Group: Double-blind trial of intravenous methylprednisolone in Guillain-Barré syndrome. Lancet 341: 586-590, 1993
20) Singh NK, Gupta A: Do corticosteroids influence the disease course or mortality in Guillain-Barré syndrome? J Assoc Physicians India 44(1): 22-24, 1996
21) Hughes RAC, Swan AV, van Doorn PA: Corticosteroids for Guillain-Barré syndrome. Cochrane Database Syst Rev CD001446, 2010
22) 日本神経学会（監): ギラン・バレー症候群 フィッシャー症候群 診療ガイドライン2013．I. ギラン・バレー症候群, 治療. 南江堂, 東京, 2013, pp82-158
23) 野村恭一: 神経疾患. 日本アフェレシス学会（編): Clinical Engineering別冊. アフェレシスマニュアル. 改訂第3版. 秀潤社. 東京, 2010, pp336-362
24) Brettle RP, Gross M, Legg NJ, Lockwood M, Pallis C: Treatment of acute polyneuropathy by plasma exchange. Lancet 2: 1100, 1978
25) Mark B, Hurwitz J, Olanow CW: Plasmapheresis in idiopathic inflamematory polyradiculoneuropathy (abstract). Neurology 30: 361, 1980
26) Ropper AH, Shahani B, Huggins CE: Improvement in four patients with acute Guillain-Barré syndrome after plasma exchange (abstract). Neurology 30: 361, 1980
27) Schoneman F, Janot C, Streiff F, Gérard A, Dureux JB, et al: Plasma exchange in Guillain-Barré syndrome ten cases. Plasmapheresis Therapy 2: 117-121, 1981
28) Valbonesi M, Garelli S, Mosconi L, Zerbi D, Celano I: Plasma exchange as a therapy for Guillain-Barré syndrome with immune complexes. Vox Sang 41: 74-78, 1981
29) The Guillain-Barré Syndrome Study Group: Plasmapheresis and acute Guillain-Barré syndrome. Neurology 35: 1096-1104, 1985
30) French Cooperative Group on Plasma Exchange in Guillain-Barré Syndrome: Efficiency of plasma exchange in Guillain-Barré syndrome: role of replacement fluids. Ann Neruol 22: 753-761, 1987
31) Raphaël JC, Chevret S, Hughes RA, Annane D: Plasma exchange for Guillain-Barré syndrome (Review). Cochrane Database Syst Rev CD001798, 2002
32) French cooperative group on plasma exchanges in Guillain-Barré syndrome: Appropriate number of plasma exchange in Guillain-Barré syndrome. Ann Neurol 41: 298-306, 1997
33) Haupt WF, Birkmann C, van der Ven C, Pawlik G: Apheresis and selective adsorption plus immunoglobulin treatment in Guillain-Barré syndrome. Ther Apher 4: 198-200, 2000
34) Diener HC, Haupt WF, Kloss TM, Rosenow F, Philipp T, et al: A preliminary, randomized, multicenter study comparing intravenous immunoglobulin, plasma exchange, and immune adsorption in Guillain-Barré syndrome. Eur Neurol 46: 107-109, 2001
35) 高 昌星: 脱髄性疾患. 脱髄患者免疫吸着療法. Annual Review神経. 中外医学社, 東京, 1994, pp242-250
36) 桑原 聡, 中島雅士, 師尾 有, 平山惠造: ギラン・バレー症候群における二重濾過法, 免疫吸着法によるプラズマフェレーシスの有用性. 臨床神経36: 289-292, 1996
37) 荒木俊彦, 中田悠皓, 楠 進, 新井裕至, 片山泰朗: ギラン・バレー症候群のトリプトファンカラムによる免疫吸着療法の検討: 抗ガングリオシド抗体の検討を含めて. 臨床神経40: 979-985, 2000
38) Takei H, Komaba Y, Araki T, Iino Y, Katayama Y: Plasma immunoadsorption therapy for Guillain-Barré syndrome: critical day for initiation. J Nihon Med Sch 69: 557-563, 2002
39) Okamiya S, Ogino M, Ogino Y, Irie S, Kanazawa N, et al: Tryptophan-immobilized column-based immunoadsorption as the choice method for plasmapheresis in Guillain-Barré syndrome. Ther Apher Dial 8: 248-253, 2004
40) Seta T, Nagayama H, Katsura K, Hamamoto M, Araki T, et al: Factors influencing outcome in Guillain-Barré syndrome: comparison of plasma adsorption against other treatments. Clin Neurol Neurosurg 107: 491-496, 2005
41) Marn Pernat A, Buturović-Ponikvar J, Svigelj V, Ponikvar R: Guillain-Barré syndrome treated by membrane plasma exchange and/or immunoadsorption. Ther Apher Dial 13: 310-313, 2009
42) Galldiks N, Dohnmen C, Neveling M, Fink GR, Haupt WF: Selective immune adsorption treatment of severe Guillain-Barré syndrome in the intensive care unit. Neurocrit Care 11: 317-321, 2009
43) 橋詰 淳, 藤岡祐介, 辻本昌史, 安井敬三, 長谷川康博, 他: Guillain-Barré症候群に対するヒト免疫グロブリン大量静注療法と血液浄化療法の有効性比較: ヒト免疫グロブリン大量静注療法の早期治療開始の利点. 神経治療26: 61-67, 2009
44) Tagawa Y, Yuki N, Hirata K: Ability to remove immunoglobulins and antiganglioside antibodies by double filtration plasmaphresis in Guillain-Barré syndrome: is it equivalent to plasma exchange? Ther Apher 1: 336-339, 1997
45) Chen WH, Yeh JH, Chiu HC: Experience of double filtration plasmaphresis in the treatment of Guillain-Barré syndrome. J Clin Apher 14: 126-129, 1999
46) Lyu RK, Chen WH, Hsieh ST: Plasma exchange versus double filtration plasmaphresis in the treatment of Guillain-Barré syndrome. Ther Apher 6: 163-166, 2002
47) Dalakas MC: The use of intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: evidence-based indications and safety profile. Pharmacol Ther 102: 177-193, 2004
48) Yu Z, Lennon VA: Mechanism of intravenous immune globulin therapy in antibody-mediated autoimmune diseases. N Engl J Med 340: 227-228, 1999
49) Kleyweg RP, van der Meché FGA, Meulstee J: Treatment of Guillain-Barré syndrome with high dose gammaglobulin. Neurology 38: 1639-1641, 1988
50) Gürses N, Uysal S, Cetinkaya F, Iş,lek I, Kalayci AG: Intravenous immunoglobulin treatment in children with Guillain-Barré syndrome. Scand J Infest Dis 27: 241-243, 1995
51) Korinthenberg R, Schessl J, Kirschner J, Mönting JS: Intravenously administered immunoglobulin in the treatment of childhood Guillain-Barré syndrome: a randomized trial. Pediatrics 116: 8-14, 2005
52) van der Meché FGA, Schmitz PIM; Guillain-Barré study group: A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré syndrome. Dutch Guillain-Barré Study Group. N Engl J Med 326: 1123-1129, 1992
53) Bril V, Ilse WK, Pearce R, Dhanani A, Sutton D, et al: Pilot trial of immunoglobulin versus plasma exchange in patients with Guillain-Barré syndrome. Neurology 46: 100-103, 1996
54) Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group: Randomized trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barré syndrome. Lancet 349: 225-230, 1997
55) 野村恭一, 濱口勝彦, 細川 武, 服部孝道, 佐藤 猛, 他: Guillain-Barré症候群に対する免疫グロブリン療法と血漿交換療法とのランダム割付け比較試験. 神経治療18: 69-81, 2001
56) Hughes RAC, Swan AV, van Doorn PA: Intravenous immunoglobulin for Guillain-Barré syndrome. Cochrane Database Syst Rev: CD002063, 2010
57) Kuitwaard K, de Gelder J, Tio-Gillen AP, Hop WC, van Gelder T, et al: Pharmacokinetics of intravenous immunoglobulin and outcome in Guillain-Barré syndrome. Ann Neurol 66: 597-603, 2009
58) 濱口勝彦, 野村恭一: ギラン・バレー症候群における献血ベニロン-Iの使用成績調査—中間報告—. 診療と新薬43: 1175-1190, 2006
59) Mendell JR, Kissel JT, Kennedy MS, Sahenk Z, Grinvalsky HT, et al: Plasma exchange and prednisone in Guillain-Barré syndrome: a controlled randomized trial. Neurology 35: 1551-1555, 1985
60) The Dutch Guillain-Barré Study Group: Treatment of Guillain-Barré syndrome with high-dose high-dose immune globulins combined with methylprednisolone: a pilot study. Ann Neurol 35: 749-752, 1994
61) van Koningsveld R, Schmitz PL, Meché FG, Visser LH, Meulstee J, et al; Dutch GBS study group: Effect of methylprednisolone when added to standard treatment with intravenous immunoglobulin for Guillain-Barré syndrome: randomized trial. Lancet 363: 192-196, 2004
62) Oczko-Walker M, Manousakis G, Wang S, Malter JS, Waclawik AJ: Plasma exchange after initial intravenous immunoglobulin treatment in Guillain-Barré syndrome: critical reassessment of effectiveness and cost-efficiency. J Clin Neuromuscul Dis 12: 55-61, 2010
63) Haupt WF, Rosenow F, van der Ven C, Borberg H, Pawlik G, et al: Sequential treatment of Guillain-Barré syndrome with extracorporeal elimination and intravenous immunoglobulin. J Neurol Sci 137: 145-149, 1996
64) Bensa S, Hadden RD, Hahn A, Hughes RA, Willison HJ: Randomized controlled trial of brain-derived neurotrophic factor in Guillain-Barré syndrome: a pilot study. Eur J Neurol 7: 423-426, 2000
65) Zhang X, Xia J, Ye H: Study of serum and CSF IL-6 and sIL-2R of Guillain-Barré syndrome patients with Tripterygium Wilfordii. Clin J Immunol 1: 53-54, 2001
66) Wollinsky KH, Hülser PJ, Brinkmeier H, Aulkemeyer P, Bössenecker W, et al: CSF filtration is an effective treatment of Guillain-Barré syndrome: a randomized clinical trial. Neurology 57: 774-780, 2001
67) Schaller B, Radziwill AJ, Steck AJ: Successful treatment of Guillain-Barré syndrome with combined administration of interferon-beta-1a and intravenous immunoglobulin. Eur Neurol 46: 167-168, 2001
68) Pritchard J, Gray IA, Idrissova ZR, Lecky BR, Sutton IJ, et al: A randomized controlled trial of recombinant Interferon-beta 1a in Guillain-Barré syndrome. Neurology 61: 1282-1284, 2003
69) Garssen MP, van Koningsveld R, van Doorn PA, Merkies IS, Scheltens-de Boer M, et al: Treatment of Guillain-Barré syndrome with mycophenolate mofetil: a pilot study. J Neurol Neurosurg Psychiarty 78: 1012-1013, 2007
70) Santiago-Casas Y, Peredo R, Vilá L: Efficacy of low-dose intravenous cyclophosphamide in systemic lupus erythematosus presenting with Guillain-Barré syndrome like acute axonal neuropathies: report of two cases. Lupus 22: 324-327, 2013
71) Halsted SK, Zitman FM, Humphreys PD, Greenshields K, Verschuuren JJ, et al: Eculizumab prevents antiganglioside antibody-mediated neuropathy in a murine model. Brain 131: 1197-1208, 2008
72) Xiao J, Simard AR, Shi F-D, Hao J: New strategies in the management of Guillain-Barré syndrome. Clin Rev Allergy Immunol 47: 274-288, 2014
73) Zhang Z, Zhang ZY, Fauser U, Schluesener HJ: Valproic acid attenuates inflammation in experimental autoimmune neuritis. Cell Mol Life Sci 65: 4055-4065, 2008
74) Yi C, Zhang Z, Wang W, Zug C, Schluesener HJ, et al: Doxycycline attenuates peripheral inflammation in rat experimental autoimmune neuritis. Neurochem Res 36: 1984-1990, 2011
75) Lin T: Effective prevention and treatment of experimental autoimmune neuritis with rapamycin. J Neurol Sci 238 (Suppl 1): S190, 2005
76) Ramkalawan H, Wang YZ, Hurbungs A, Yang YF, Tian FF, et al: Pioglitazone, PPARγ agonist, attenuates experimental autoimmune neuritis. Inflammation 35: 1338-1347, 2012
77) Taylor JM, Pollard JD: Soluble TNFR1 inhibits the development of experimental autoimmune neuritis by modulating blood-nerve-barrier permeability and inflammation. J Neuroimmunol 183: 118-124, 2007
78) Miyamoto K, Oka N, Kawasaki T, Miyake S, Yamamura T, et al: New cyclooxygenase-2 inhibitors for treatment of experimental autoimmune neuritis. Muscle Nerve 25: 280-282, 2002
79) Zhang Z, Zhang ZY, Schlusener HJ: Compound A, a plant origin ligand of glucocorticoid receptors, increases regulatory T cells and M2 macrophages to attenuate experimental autoimmune neuritis with reduced side effects. J Immunol 183: 3081-3091, 2009
80) Zhnag ZY, Zhang Z, Schlusener HJ: MS-275, an histone deacetylase inhibitor, reduces the inflammatory reaction in rat experimental autoimmune neuritis. Neuroscience 169: 370-377, 2010
81) Sarky JP, Richards MP, Stubbs EB Jr: Lovastatin attenuates nerve injury in an animal model of Guillain-Barré syndrome. J Neurochem 100: 1265-1277, 2007
82) Li XL, Dou YC, Liu Y, Shi CW, Cao LL, et al: Atorvastatin ameliorates experimental autoimmune neuritis by decreased Th1/Th17 cytokines and Up-regulatory T regulated cells. Cell Immunol 271: 455-461, 2011
83) Ahn M, Moon C, Jeong C, Matsumoto Y, Koh CS, et al: Upregulation of erythropoietin in rat peripheral nervous system with experimental autoimmune neuritis. Brain Res 1333: 82-90, 2010
84) Pineda AA, Minohara M, Kawamura N, Matsushita T, Yamasaki R, et al: Preventive and therapeutic effects of the selective Rho-kinase inhibitor fasudil on experimental autoimmune neuritis. J Neurol Sci 306: 115-120, 2011
85) 木澤英樹, 野村恭一, 島津邦男: ONO-2506の実験的自己免疫性神経炎に対する予防および治療効果. 神経治療18: 259-266, 2001
86) Zhang ZY, Zhnag Z, Zug C, Nuesslein-Hildesheim B, Leppert D, et al: AUY954, a selective S1P(1) modulator, prevents experimental autoimmune neuritis. J Neuroimmunol 216: 59-65, 2009
87) Zhang Z, Zhnag ZY, Fauser U, Schluesener HJ: FTY720 ameliorates experimental autoimmune neuritis by inhibition of lymphocyte and monocyte infiltration into peripheral nerves. Exp Neurol 210: 681-690, 2008
88) Zou LP, Abbas N, Volkmann I, Nennesmo I, Levi M, et al: Suppression of experimental autoimmune neuritis by ABR-215062 is associated with altered Th1/Th2 balance and inhibited migration of inflammatory cells into the peripheral nerve tissue. Neuropharmacology 42: 731-739, 2002
89) Zou LP, Deretzi G, Pelidou SH, Levi M, Wahren B, et al: Rolipram suppresses experimental autoimmune neuritis and prevents relapses in Lewis rats. Neuropharmacology 39: 324-333, 2000
90) Karpati T, Karussis D, Abramsky O, Mizrahi-Koll R, Arbell I, et al: Inhibition of experimental autoimmune neuritis by the immunomodulator linomide. Immunol Lett 63: 141-145, 1998
91) Schmidt J, Elflein K, Stienekemeier M, Rodriguez-Palmero M, Schneider C, et al: Treatment and prevention of experimental autoimmune neuritis with superagonistic CD28-specific monoclonal antibodies. J Neuroimmunol 140: 143-152, 2003
92) Yu S, Chen Z, Mix E, Zhu SW, Winblad B, et al: Neutralizing antibodies to IL-18 ameliorate experimental autoimmune neuritis by counter-regulation of autoreactive Th1 responses to peripheral myelin antigen. J Neuropathol Exp Neurol 61: 614-622, 2002
93) Usuki S, Taguchi K, Thompson SA, Chapman PB, Yu RK: Novel anti-idiotype antibody therapy for lipooligosaccharide-induced experimental autoimmune neuritis: use relevant to Guillain-Barré syndrome. J Neurosci Res 88: 1651-1663, 2010
94) Zou LP, Zhn J, Deng GM, Levi M, Wahren B, et al: Treatment with P2 protein peptide 57-81 by nasal route is effective in Lewis rat experimental autoimmune neuritis. J Neuroimmunol 85: 137-145, 1998
掲載雑誌情報
